Sumimoto et al. demonstrated that siRNAs targeting KRAS or ERK2 and the MEK inhibitor decreased PD-L1 expression in KRAS-mutant NSCLC with PD-L1 overexpression [95]. This evidence concerns the gene MAPK1 and non-small cell lung carcinoma.